- Exchange: OTC US
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Snapshot for Hard to Treat Diseases Inc/FL (HTDS)
| Open: | - | Day's Range: | - | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 0.0001 | 52wk Range: | 0.0001 - 0.0001 | 1-Yr Rtn: | - |
Key Statistics for HTDS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(-) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 0.00 |
| Shares Outstanding (M) | 5,482.34 |
| 30 Day Average Volume | 0 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for HTDS
No data available
Company Profile & Key Executives for HTDS
Hard to Treat Diseases Incorporated holds the international marketing rights, except South Korea, to Tubercin, an immunostimulant. The Company's product is a nasal spray developed for combating cancer and rheumatoid arthritis, targeted to the holistic product market. Hard to Treat Diseases is also seeking to market its chemical process for the disposal and recycling of Styrofoam.
| Terry YuanChief Executive Officer | Tony BiancoCOO |
| Sanja PekovicChief Project Scientist | Mirjana StojiljkovicMedical Advisor |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
HTDS News
-
Industry News
No stories found
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page